Abstract
| Original language | English |
|---|---|
| Pages (from-to) | 6997–7008 |
| Number of pages | 12 |
| Journal | Oncogene |
| Volume | 25 |
| Issue number | 52 |
| DOIs | |
| Publication status | Published - 2006 |
| MoE publication type | A1 Journal article-refereed |
Fingerprint
Keywords
- head and neck cancer
- cDNA microarrays
- oligonucleotide microarrays
- comparative genomic hybridization
Cite this
}
Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses. / Järvinen, A.-K.; Autio, R.; Haapa-Paananen, Saija; Wolf, Maija; Saarela, M.; Grénman, R.; Leivo, I.; Kallioniemi, Olli; Mäkitie, A. A.; Monni, O. (Corresponding Author).
In: Oncogene, Vol. 25, No. 52, 2006, p. 6997–7008.Research output: Contribution to journal › Article › Scientific › peer-review
TY - JOUR
T1 - Identification of target genes in laryngeal squamous cell carcinoma by high-resolution copy number and gene expression microarray analyses
AU - Järvinen, A.-K.
AU - Autio, R.
AU - Haapa-Paananen, Saija
AU - Wolf, Maija
AU - Saarela, M.
AU - Grénman, R.
AU - Leivo, I.
AU - Kallioniemi, Olli
AU - Mäkitie, A. A.
AU - Monni, O.
PY - 2006
Y1 - 2006
N2 - Molecular mechanisms contributing to initiation and progression of head and neck squamous cell carcinoma are still poorly known. Numerous genetic alterations have been described, but molecular consequences of such alterations in most cases remain unclear. Here, we performed an integrated high-resolution microarray analysis of gene copy number and expression in 20 laryngeal cancer cell lines and primary tumors. Our aim was to identify genetic alterations that play a key role in disease pathogenesis and pinpoint genes whose expression is directly impacted by these events. Integration of DNA level data from array-based comparative genomic hybridization with RNA level information from oligonucleotide microarrays was achieved with custom-developed bioinformatic methods. High-level amplifications had a clear impact on gene expression. Across the genome, overexpression of 739 genes could be attributed to gene amplification events in cell lines, with 325 genes showing the same phenomenon in primary tumors including FADD and PPFIA1 at 11q13. The analysis of gene ontology and pathway distributions further pinpointed genes that may identify potential targets of therapeutic intervention. Our data highlight genes that may be critically important to laryngeal cancer progression and offer potential therapeutic targets.
AB - Molecular mechanisms contributing to initiation and progression of head and neck squamous cell carcinoma are still poorly known. Numerous genetic alterations have been described, but molecular consequences of such alterations in most cases remain unclear. Here, we performed an integrated high-resolution microarray analysis of gene copy number and expression in 20 laryngeal cancer cell lines and primary tumors. Our aim was to identify genetic alterations that play a key role in disease pathogenesis and pinpoint genes whose expression is directly impacted by these events. Integration of DNA level data from array-based comparative genomic hybridization with RNA level information from oligonucleotide microarrays was achieved with custom-developed bioinformatic methods. High-level amplifications had a clear impact on gene expression. Across the genome, overexpression of 739 genes could be attributed to gene amplification events in cell lines, with 325 genes showing the same phenomenon in primary tumors including FADD and PPFIA1 at 11q13. The analysis of gene ontology and pathway distributions further pinpointed genes that may identify potential targets of therapeutic intervention. Our data highlight genes that may be critically important to laryngeal cancer progression and offer potential therapeutic targets.
KW - head and neck cancer
KW - cDNA microarrays
KW - oligonucleotide microarrays
KW - comparative genomic hybridization
U2 - 10.1038/sj.onc.1209690
DO - 10.1038/sj.onc.1209690
M3 - Article
VL - 25
SP - 6997
EP - 7008
JO - Oncogene
JF - Oncogene
SN - 0950-9232
IS - 52
ER -